HER2+ Breast Cancer | Specialty

Case Study: Treating HR+ and HER2- Breast Cancer

June 9th 2013

Paclitaxel With Pertuzumab Plus Trastuzumab in MBC

June 9th 2013

Case Study: Treating HER2-Positive MBC, Part II

June 9th 2013

Case Study: Treating HER2-Positive MBC, Part I

June 9th 2013

Treatment With Eribulin in Metastatic Breast Cancer

June 9th 2013

MA.31 Trial: Taxane With Lapatinib or Trastuzumab

June 9th 2013

CLEOPATRA Trial: Frontline Pertuzumab for HER2+ MBC

June 9th 2013

Frontline T-DM1 in HER2+ Metastatic Breast Cancer

June 9th 2013

EMILIA Trial: T-DM1 in Metastatic Breast Cancer

June 9th 2013

Management of mTOR Inhibitor Side Effects in Breast Cancer

June 9th 2013

BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer

June 9th 2013

Combination of Anastrozole and Fulvestrant in MBC

June 9th 2013

Introduction and Exploration of Fulvestrant in Breast Cancer

June 9th 2013

Revisiting HER2: Recent Research Shakes Views on Famed Marker

June 5th 2013

New research suggests that HER2-targeted drugs may actually have much broader applications, benefiting patients who are not designated HER2-positive by routine testing.

Dr. Baselga Discusses Upcoming BOLERO-3 Data

April 18th 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

Dr. Ron Bose on HER2 Gene Mutations in Breast Cancer

March 8th 2013

Ron Bose, MD, PhD, from the Siteman Cancer Center, discusses the prevalence of HER2 gene mutations in patients diagnosed with breast cancer.

HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer

February 5th 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

Guideline Adherence Is Vital to HER2 Accuracy

January 31st 2013

Efforts to improve guidelines continue for HER2 testing and the evaluation of whether patients' tumors are estrogen receptor-positive and progesterone receptor-positive.

Addition of PI3K Inhibitor May Prevent or Delay Resistance to Therapy in HER2+ Breast Cancer

January 23rd 2013

A new study found that patients with HER2-positive breast cancer who are receiving anti-HER2 therapy could prevent or delay resistance when a phosphatidylinositol-3 kinase (PI3K) inhibitor is added during treatment.

Lapatinib Plus Trastuzumab Bests Lapatinib Monotherapy in HER2-Positive Metastatic Breast Cancer

November 7th 2012

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.